Mania requires rapid treatment, but side effects often undermine adherence. Learn practical strategies to improve tolerability and when to consider off-label or behavioral options.
What if a patient’s most traumatic experience doesn’t meet DSM-5 criteria? This study explores how other life events can trigger PTSD-level symptoms—challenging how we define trauma.
When standard treatments fall short in alcohol use disorder, could a prazosin–cyproheptadine combination help? A new randomized trial suggests this pairing may significantly reduce high-risk drinking.
GLP-1 agonists have transformed obesity care—now emerging research suggests they may also reverse antipsychotic-induced weight gain without worsening psychiatric symptoms.
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of Psych Partners. He maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.webp?t=1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
